A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes
Kallmann syndrome is the result of innate genetic defects in the fibroblast growth factor (FGF) regulated signaling network causing diminished signal transduction. One of the rare mutations associated with the syndrome alters the Sprouty (Spry)4 protein by converting the serine at position 241 into...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/4/2145 |
| _version_ | 1797395731453050880 |
|---|---|
| author | Astrid Stütz Anna Z. M. Kamptner Hedwig Sutterlüty |
| author_facet | Astrid Stütz Anna Z. M. Kamptner Hedwig Sutterlüty |
| author_sort | Astrid Stütz |
| collection | DOAJ |
| description | Kallmann syndrome is the result of innate genetic defects in the fibroblast growth factor (FGF) regulated signaling network causing diminished signal transduction. One of the rare mutations associated with the syndrome alters the Sprouty (Spry)4 protein by converting the serine at position 241 into a tyrosine. In this study, we characterize the tyrosine Spry4 mutant protein in the primary human embryonic lung fibroblasts WI-38 and osteosarcoma-derived cell line U2OS. As demonstrated in a cell signaling assay, Spry4 gains the capability of inhibiting FGF, but not epithelial growth factor (EGF)-induced signaling as a consequence of the tyrosine substitution. Additionally, migration of normal embryonic lung fibroblasts and osteosarcoma-derived cells is potently inhibited by the tyrosine Spry4 variant, while an effect of the wildtype Spry4 protein is hardly measureable. Concerning cell proliferation, the unaltered Spry4 protein is ineffective to influence the WI-38 cells, while the mutated Spry4 protein decelerates the cell doubling. In summary, these data emphasize that like the other mutations associated with Kallmann syndrome the described Spry4 mutation creates a hyperactive version of a selective inhibitory molecule and can thereby contribute to a weakened FGF signaling. Additionally, the study pinpoints a Spry4 variation expanding the applicability of Spry4 in a potential cancer therapy. |
| first_indexed | 2024-03-09T00:39:52Z |
| format | Article |
| id | doaj.art-c199c490c0694cd39794a85911111564 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T00:39:52Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-c199c490c0694cd39794a859111115642023-12-11T17:54:16ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-02-01224214510.3390/ijms22042145A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected ProcessesAstrid Stütz0Anna Z. M. Kamptner1Hedwig Sutterlüty2Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, AustriaInstitute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, AustriaInstitute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, AustriaKallmann syndrome is the result of innate genetic defects in the fibroblast growth factor (FGF) regulated signaling network causing diminished signal transduction. One of the rare mutations associated with the syndrome alters the Sprouty (Spry)4 protein by converting the serine at position 241 into a tyrosine. In this study, we characterize the tyrosine Spry4 mutant protein in the primary human embryonic lung fibroblasts WI-38 and osteosarcoma-derived cell line U2OS. As demonstrated in a cell signaling assay, Spry4 gains the capability of inhibiting FGF, but not epithelial growth factor (EGF)-induced signaling as a consequence of the tyrosine substitution. Additionally, migration of normal embryonic lung fibroblasts and osteosarcoma-derived cells is potently inhibited by the tyrosine Spry4 variant, while an effect of the wildtype Spry4 protein is hardly measureable. Concerning cell proliferation, the unaltered Spry4 protein is ineffective to influence the WI-38 cells, while the mutated Spry4 protein decelerates the cell doubling. In summary, these data emphasize that like the other mutations associated with Kallmann syndrome the described Spry4 mutation creates a hyperactive version of a selective inhibitory molecule and can thereby contribute to a weakened FGF signaling. Additionally, the study pinpoints a Spry4 variation expanding the applicability of Spry4 in a potential cancer therapy.https://www.mdpi.com/1422-0067/22/4/2145Spry4Sprouty proteinKallmann syndromeFGFR1FGF-mediated signalingMAPK pathway |
| spellingShingle | Astrid Stütz Anna Z. M. Kamptner Hedwig Sutterlüty A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes International Journal of Molecular Sciences Spry4 Sprouty protein Kallmann syndrome FGFR1 FGF-mediated signaling MAPK pathway |
| title | A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes |
| title_full | A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes |
| title_fullStr | A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes |
| title_full_unstemmed | A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes |
| title_short | A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes |
| title_sort | sprouty4 mutation identified in kallmann syndrome increases the inhibitory potency of the protein towards fgf and connected processes |
| topic | Spry4 Sprouty protein Kallmann syndrome FGFR1 FGF-mediated signaling MAPK pathway |
| url | https://www.mdpi.com/1422-0067/22/4/2145 |
| work_keys_str_mv | AT astridstutz asprouty4mutationidentifiedinkallmannsyndromeincreasestheinhibitorypotencyoftheproteintowardsfgfandconnectedprocesses AT annazmkamptner asprouty4mutationidentifiedinkallmannsyndromeincreasestheinhibitorypotencyoftheproteintowardsfgfandconnectedprocesses AT hedwigsutterluty asprouty4mutationidentifiedinkallmannsyndromeincreasestheinhibitorypotencyoftheproteintowardsfgfandconnectedprocesses AT astridstutz sprouty4mutationidentifiedinkallmannsyndromeincreasestheinhibitorypotencyoftheproteintowardsfgfandconnectedprocesses AT annazmkamptner sprouty4mutationidentifiedinkallmannsyndromeincreasestheinhibitorypotencyoftheproteintowardsfgfandconnectedprocesses AT hedwigsutterluty sprouty4mutationidentifiedinkallmannsyndromeincreasestheinhibitorypotencyoftheproteintowardsfgfandconnectedprocesses |